Last Updated : February 26, 2025
Details
Generic Name:
osimertinib
Project Status:
Received
Therapeutic Area:
Unresectable (stage III) non-small cell lung cancer
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Tagrisso
Project Line:
Reimbursement Review
Project Number:
PC0398-000
Call for patient/clinician input closed:
Tumour Type:
Lung
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations (either alone or in combination with other EGFR mutations) and whose disease has not progressed during or following platinum-based chemoradiation therapy (CRT)
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For
the treatment of patients with locally advanced, unresectable (stage III)
non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor
receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
(either alone or in combination with other EGFR mutations) and whose disease
has not progressed during or following platinum-based chemoradiation therapy
(CRT).
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 02, 2025 |
|---|---|
| Call for patient/clinician input closed | February 24, 2025 |
| Submission received | February 13, 2025 |
| Submission accepted | - |
Last Updated : February 26, 2025